Evaluate Pharma offers clients forecasts of the pharma industry in its annual World Preview.
The top 10 R&D spenders for 2024:
1. Johnson & Johnon ($9.9 billion)
2. Roche ($9.9 billion)
3. Merck ($9.2 billion)
4. Novartis ($9.2 billion)
5. Pfizer ($8.9 billion)
6. GlaxoSmithKline ($6.8 billion)
7. Bristol-Myers Squibb ($6.7 billion)
8. Sanofi ($6.7 billion)
9. Eli Lilly ($6.1 billion)
10. AstraZeneca ($5.9 billion)
More articles on pharmacy:
Lupin recalls 18,408 bottles of antibiotic in US
Bluebird Bio prices gene therapy at $1.8M
10 hospitals seeking pharmacy leaders
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.